Synthetic Biologics Announces Formation of Scientific Advisory Board to Advance Oncology Pipeline

Synthetic Biologics, Inc.

Scientific Advisory Board of Leading Experts in Oncolytic Adenoviruses and Gene Therapies Strengthens Transformative Clinical Development Strategy and Expansion to Oncology

ROCKVILLE, Md., May 05, 2022 (GLOBE NEWSWIRE) — Synthetic Biologics, Inc. (NYSE American: SYN), a diversified clinical-stage company developing therapies designed to treat diseases in areas of high unmet need, today announced the strengthening of its oncology leadership team with the formation of a Scientific Advisory Board (SAB) composed of leading experts in oncolytic viruses and gene therapies. The SAB will work cohesively with Synthetic Biologics’ leadership team to support the company’s transformative clinical development strategy and its expansion into oncology.

“We are honored to work with this group of world-class scientific leaders to advise us in the development of Synthetic Biologics’ unique clinical-stage oncolytic viruses optimized for intravenous delivery,” said Steven A. Shallcross, Chief Executive Officer of Synthetic Biologics. . “These distinguished leaders have made groundbreaking scientific advances in their respective fields of oncology, immunology and gene therapy, and we look forward to their guidance as Synthetic Biologics advances its oncolytic adenovirus development program. (OV) to fight devastating cancers with high unmet need.

The founding members of the SAB are included below.

Chair: Ramon Alemany, Ph.D., is Head of the Immunotherapy and Virotherapy Group at the Translational Research Laboratory of the Institut Catala d’Oncologia (ICO) and the Institut de Investigacio Biomedica de Bellvitage (IDIBELL). Dr. Alemany is co-founder of VCN Biosciences and is an internationally recognized expert in oncolytic adenoviruses for the treatment of cancer. He has held various research positions at leading academic institutions including MD Anderson Cancer Center, Baxter Healthcare Group, and the University of Alabama at Birmingham. Dr. Alemany received his doctorate and license from the University of Barcelona.

Member: Mark S. Blumenkranz, MD, MMS, is HJ Smead Professor Emeritus in the Department of Ophthalmology at Stanford University. Dr. Blumenkranz was an early innovator in vitrectomy techniques to treat complex forms of retinal detachment and helped usher in the modern era of intravitreal and surgical adjuvant drug therapy. He served on the editorial boards of The American Journal of Ophthalmology, Retina, Ophthalmologyand Graefe Archives for Ophthalmology. Dr. Blumenkranz earned his MD from Brown University.

Member: Ennio Antonio Chiocca, MD, Ph.D., is Harvey W. Cushing Professor of Neurosurgery at Harvard Medical School, Chief Neurosurgeon and Chairman of the Department of Neurosurgery, and Co-Director of the Neuroscience Institute at Brigham and Women’s Faulkner Hospital . He is also the Surgical Director of the Neuro-Oncology Center at the Dana-Farber Cancer Institute. His research focuses on the development of new genetic and immunotherapeutic approaches for malignant brain tumors, with a particular interest in the design of viruses capable of killing tumor cells without affecting normal brain cells. Dr. Chiocca received his MD from the University of Texas at Houston School of Medicine and the Graduate School of Biomedical Sciences.

Member: Daniel DiMaio, MD, Ph.D., is Waldemar Von Zedtwitz Professor of Genetics and Professor of Molecular Biophysics and Biochemistry, and Therapeutic Radiology at the Yale School of Medicine, as well as Senior Advisor to the Director, Yale Cancer Center. Dr. DiMaio brings an unparalleled depth of knowledge and experience in the fields of human genetics, tumor virology and cancer research. Dr. DiMaio received his Ph.D. from Johns Hopkins University School of Medicine and his BSc from Yale University.

Member: Tom Dubensky, Ph.D., President of Tempest Therapeutics, a clinical-stage biotechnology company developing small molecules to treat cancer through mechanisms that directly kill tumor cells and activate tumor-specific immunity. He was the founding CEO of Tempest and brings significant industry expertise in discovery, development and clinical application in cancer immunotherapy and infectious disease indications. Dr. Dubensky received his Ph.D. from the University of Colorado Health Sciences Center.

Member: Josep Tabernero, MD, Ph.D., is Head of the Department of Medical Oncology at the University Hospital of Vall d’Hebron, Director of the Institute of Oncology of Vall d’Hebron (VHIO) and Professor of medicine at UVic. Dr. Tabernero’s research focuses on the potentiation of molecular therapies and the targeting of specific oncoproteins for personalized care. Dr. Tabernero sits on the editorial boards of various leading journals, including Annals of Oncology, ESMO Open, Cancer Discovery and Clinical cancer research. Dr. Tabernero obtained his MD and PhD from the Universitat Autonoma de Barcelona, ​​Spain.

About Synthetic Biologics, Inc.

Synthetic Biologics, Inc. (NYSE American: SYN) is a diversified clinical-stage company that develops therapeutic products designed to treat diseases in areas of high unmet need. The Company recently completed the acquisition of VCN Biosciences, SL (VCN), which is developing a novel oncolytic adenovirus (OV) platform designed for intravenous (IV), intravitreal and antitumor administration to trigger tumor cell death, improve access to co-administered cancer therapies against the tumor and promote a robust anti-tumor response supported by the patient’s immune system. The Company’s lead clinical candidates are: (1) VCN-01, an oncolytic adenovirus engineered to selectively and aggressively replicate in tumor cells and to degrade the tumor stromal barrier that serves as an important physical and immunosuppressive barrier to treatment cancer; (2) SYN-004 (ribaxamase) which is designed to degrade certain IV beta-lactam antibiotics commonly used in the gastrointestinal (GI) tract to prevent (a) microbiome damage, (b) Clostridioides difficile infection (CDI), (c) proliferation of pathogenic organisms, (d) emergence of antimicrobial resistance (AMR), and (e) acute graft versus host disease (aGVHD) in transplant recipients of allogeneic hematopoietic cells (HCT); and (3) SYN-020, a recombinant oral formulation of the intestinal alkaline phosphatase (IAP) enzyme produced under cGMP conditions and intended to treat both local gastrointestinal diseases and systemic diseases. For more information, please visit the Synthetic Biologics website at www.syntheticbiologics.com.

Forward-looking statements

This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. In some instances, forward-looking statements may be identified by words such as “may”, “should”, “potential”, “continuing”, “expects”, “anticipates”, “intends”, “plans”, “believes”, “estimates” and similar expressions, and includes statements regarding the progress of the adenovirus development program oncolytics (OV) from Synthetic Biologics and the contributions to be made by the members of the scientific council. These forward-looking statements are based on management’s expectations and assumptions as of the date of this press release and are subject to a number of risks and uncertainties, many of which are difficult to predict, which could cause actual results differ materially from current expectations and assumptions from those expressed or implied by any forward-looking statement. Important factors that could cause actual results to differ materially from current expectations include, among others, the success of the combined business of Synthetic Biologics and VCN; product candidates from Synthetic Biologics and VCN demonstrating safety and efficacy, and results consistent with prior results; the ability to initiate and complete clinical trials on time and achieve desired results and benefits; continue enrollment in clinical trials as planned; the ability to obtain regulatory approval for the commercialization of product candidates or to comply with ongoing regulatory requirements, regulatory limitations on the ability of Synthetic Biologics and VCN to promote or commercialize their product candidates for the specific indications; the acceptance of product candidates in the marketplace and the successful development, commercialization or sale of Synthetic Biologics’ and VCN’s products; developments by competitors that render such products obsolete or uncompetitive; the ability of Synthetic Biologics and VCN to maintain license agreements; the continued maintenance and growth of Synthetic Biologics’ and VCN’s patent heritage; the ability to continue to remain well funded; and other factors described in Synthetic Biologics’ Annual Report on Form 10-K for the fiscal year ended December 31, 2021 and its other filings with the SEC, including subsequent periodic reports on Forms 10-Q and 8-K. The information in this release is provided only as of the date of this release, and Synthetic Biologics undertakes no obligation to update any forward-looking statements contained in this release as a result of new information, future events or otherwise. except as required by law. .

For more information, please contact:

Investor Relations:

Chris Calabrian

LifeSci Advisors, LLC

[email protected]

917-680-5608

Comments are closed.